Patient - PACT
New Clinical Trial and Research

Trial title	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial
Trial synopsis	Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by difficulty breathing and persistent dry cough. Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy. Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.
Investigational medicinal product, comparator and randomisation	RVT-1601
Disease target	Idiopathic pulmonary fibrosis (IPF)
Sponsor	Respivant Sciences GmbH
Duration	28 Weeks
Trial Status	Recruiting
Lead site(s) in Australia	Mater Research, Royal Adelaide Hospital
Lead site(s) in New Zealand	Otago University
Additional sites	Lung Research QLD Alfred Hospital, VIC Westmead Hospital, NSW Royal Prince Alfred Hospital, NSW Frankston Hospital – Peninsula Health, VIC TrialsWest, WA Austin Hospital, VIC Fiona Stanley Hospital, WA Waikato Hospital, NZ Greenlane Clinical Centre, NZ
Contact	pactcoordinator@cre-pf.org.au